Skip to main navigation

Our Science
Pipeline & Programs
About Us
Life at Arvinas
Careers
Patients
Arvinas Early Career Researcher Award
Investors + Media

Investors + Media: Press Releases

Press Releases

Year

August 4, 2022

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 1, 2022

Arvinas Appoints John Northcott as Chief Commercial Officer

June 2, 2022

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

June 1, 2022

Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations

May 5, 2022

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 3, 2022

Arvinas to Present at Bank of America Securities 2022 Healthcare Conference

March 4, 2022

Arvinas to Present at Upcoming Investor Conferences

February 28, 2022

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 17, 2022

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

February 14, 2022

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting

Pagination

Current page 1
Page 2
Next page
Last page

Tools

Email Alerts
RSS Feeds
Print Page
Email Page

Leading the way in targeted protein degradation therapeutics.

Join our team of experts

Follow Us https://www.linkedin.com/company/arvinas/ https://twitter.com/ArvinasInc

©2022. All Rights Reserved.

Contact Privacy Policy Terms & Conditions